SUVN-
502 is a novel, potent, and selective 5-HT6 receptor antagonist with
Ki of 1.71 nM and exhibited antagonist like inhibition with EC50
of 0.103 mM. SUVN-502 is effective in animal models of cognition. In
microdialysis studies, SUVN-502 enhanced brain acetylcholine and glutamate
levels in rat ventral hippocampus and frontal cortex. SUVN-502 has completed
all regulatory safety and toxicity studies.
5-HT6
receptor a member of serotonin family predominates in brain regions associated
with cognition and behavior. The blockade of 5-HT6 receptors leads
to an improvement of cognitive performance in a wide variety of learning and
memory paradigms.
The
tolerability of SUVN-502 upto highest dose administered was considered as very
good. No serious adverse events occurred. No clinically significant changes or
study medication related abnormalities were observed with respect to ECG’s and
laboratory evaluations. It is in Phase I/II trials and being developed as a treatment for Alzheimer's disease (AD).
For
more details, order the pdf by sending an email at sharma.rajan@gmail.com.
Report has all the features that this site has provided to its users such as
structure, synthesis, and activity results.
For FAQ’s
